What is the appropriate stopping and restarting protocol for apixaban (Eliquis) before arthroscopic knee surgery with anterior cruciate ligament (ACL) reconstruction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Perioperative Apixaban Management for Arthroscopic ACL Reconstruction

For arthroscopic knee surgery with ACL reconstruction, stop Eliquis (apixaban) 48 hours (2 days) before surgery and restart 24-48 hours after surgery once adequate hemostasis is achieved.

Pre-operative Management

Timing of Discontinuation

Arthroscopic ACL reconstruction is classified as a high bleeding-risk procedure due to the intra-articular nature, potential for significant hemarthrosis, and need for precise surgical hemostasis 1, 2.

Stop apixaban 48 hours before surgery (skip 4 doses if taking twice daily) 1, 2, 3. This means:

  • If surgery is scheduled for Monday morning, take the last dose on Saturday morning
  • The FDA label specifically states discontinuation "at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding" 2

Key Considerations for Extended Interruption

You may need to extend the interruption period beyond 48 hours if the patient has:

  • Creatinine clearance < 50 mL/min - Consider stopping 72 hours (3 days) before surgery 1
  • Age ≥ 80 years - May require longer clearance time 4
  • Concurrent P-glycoprotein or CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) - These impair apixaban clearance 1, 2

What NOT to Do

Do not use heparin bridging - This is explicitly not recommended for DOAC interruption and only increases bleeding risk without reducing thrombotic events 1, 2. The PAUSE study demonstrated excellent safety outcomes without bridging 1, 5.

Do not perform neuraxial anesthesia (spinal/epidural) if there is any possibility of residual apixaban effect, particularly in elderly patients or those with renal impairment 4, 2.

Post-operative Management

Timing of Resumption

Restart apixaban 24-48 hours after surgery once adequate surgical hemostasis is established 1, 2, 3. The specific timing depends on:

  • 24 hours post-op: If hemostasis is excellent and bleeding risk is minimal
  • 48 hours post-op: Standard approach for high bleeding-risk procedures like ACL reconstruction 1
  • Up to 72 hours post-op: If there are ongoing concerns about hemostasis 4

Bridging with Prophylactic Anticoagulation

If VTE prophylaxis is needed during the interruption period:

  • Use prophylactic-dose LMWH or fondaparinux starting 6+ hours post-operatively 4
  • When restarting therapeutic apixaban, give the first dose 12 hours after the last prophylactic LMWH dose to avoid overlap 4
  • Avoid overlapping therapeutic doses of different anticoagulants 4

Special Considerations for ACL Surgery

Recent evidence suggests that age ≥ 40 years is a significant risk factor for DVT after ACL reconstruction, with one study showing DVT incidence of 18.8% without prophylaxis versus 4.2% with anticoagulation in this age group 6. However, your patient is already on therapeutic anticoagulation, so the focus is on minimizing interruption time while ensuring surgical safety.

Clinical Outcomes Data

The PAUSE study protocol (which forms the basis of current guidelines) demonstrated excellent safety with this approach 1, 5:

  • Arterial thromboembolism rate: 0.16% (95% CI: 0-0.48%)
  • Major bleeding rate: 1.35% (95% CI: 0-2.0%)

Recent real-world data confirms that 48-hour interruption achieves clinically insignificant anticoagulation levels in 92.4% of patients, with only 7.6% having levels ≥30 ng/mL pre-operatively 7. Notably, apixaban had slightly higher rates of residual anticoagulation (13.1%) compared to other DOACs 7.

Critical Pitfalls to Avoid

  1. Don't measure apixaban levels routinely - Only consider if surgery becomes urgent/emergent within 24 hours of last dose 1
  2. Don't use standard coagulation tests (PT/INR/aPTT) - These are insensitive for apixaban and may falsely reassure you 1
  3. Don't restart too early - Premature resumption significantly increases bleeding risk in the critical first 24-48 hours 2
  4. Don't forget to assess renal function - This is the single most important factor affecting apixaban clearance and should be checked pre-operatively 1, 4

Algorithm Summary

Pre-operative:
├─ Normal renal function (CrCl >50) → Stop 48 hours before
├─ CrCl 30-50 mL/min → Stop 72 hours before  
└─ Age ≥80 or drug interactions → Consider 72 hours

Post-operative:
├─ Excellent hemostasis → Resume 24 hours after
├─ Standard hemostasis → Resume 48 hours after
└─ Hemostasis concerns → Resume up to 72 hours after

1, 4, 2, 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.